Dabogratinib (TYRA-300) 60mg Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: June 2, 2026

The clinical evidence base for Dabogratinib (TYRA-300) 60mg comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Non-Muscle Invasive Bladder Neoplasms. Most recent publication: Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma., J Urol, 2024.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
Matin SF, Adibi M, Shah AY, et al. · J Urol · 2024
PubMed: PMID 38573872 · NCT05544552 (SURF301) · Non-Muscle Invasive Bladder Neoplasms

Publications by year

2024–2024: 1 publications.

2024

Publications by indication

Non-Muscle Invasive Bladder Neoplasms (1)

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
J Urol · 2024 · PMID 38573872 · NCT05544552

Publications by journal

J Urol1 paper

All Dabogratinib (TYRA-300) 60mg publications (1)

2024 (1 paper)

Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma.
Matin SF, Adibi M, Shah AY, et al. · J Urol · 2024 · Derived
PubMed: PMID 38573872 · NCT05544552 (SURF301) · Non-Muscle Invasive Bladder Neoplasms

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 02 Jun 2026 17:33:25 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).